Many DaVita HealthCare Partners Inc.(DVA) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Company shares were Downgraded by Robert W. Baird on Dec 13, 2016 to Neutral, Raises Price Target to $ 69 from a previous price target of $68 .
Company has reported several Insider transactions to the SEC, on Aug 11, 2016, Michael David Staffieri (COO, Kidney Care) sold 20,262 shares at 73.09 per share price.On Jul 13, 2016, Jeanine Marie Jiganti (Chief Compliance Officer) sold 1,291 shares at 78.51 per share price.On May 26, 2016, Pamela M Arway (director) sold 10,824 shares at 77.16 per share price.
DaVita HealthCare Partners Inc Last issued its quarterly earnings results on Nov 2, 2016. The company reported $0.95 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $0.93. The company had revenue of $3730.58 million for the quarter, compared to analysts expectations of $3723.95 million. The companys revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.
DaVita Inc. (NYSE:DVA) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.22 by 9 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 5 Brokerage Firms have advised hold.
DaVita Inc. (NYSE:DVA) should head towards $66.71 per share according to 7 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $54 per share. The higher price estimate target is at $75 according to the Analysts.
DaVita Inc. (NYSE:DVA) witnessed a decline in the market cap on Tuesday as its shares dropped 0.12% or 0.08 points. After the session commenced at $64.62, the stock reached the higher end at $65.06 while it hit a low of $64.57. With the volume soaring to 1,604,447 shares, the last trade was called at $64.73. The company has a 52-week high of $78.77. The company has a market cap of $12,778 million and there are 197,400,000 shares in outstanding. The 52-week low of the share price is $54.5.
DaVita Inc. is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a provider of kidney care, delivering dialysis services for chronic kidney failure and end stage renal disease primarily in the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks primarily in California, Nevada, New Mexico, Florida, Colorado and Washington. DaVita Inc., formerly known as DaVita HealthCare Partners Inc., is headquartered in Denver, Colorado.